Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study

The duration of adjuvant imatinib for high-risk patients with gastrointestinal stromal tumors (GISTs) is still controversial. Therefore, we retrospectively analyzed the data of high-risk patients with GISTs to investigate the appropriate duration. All 185 patients were divided into 4 groups: <1 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Rui, Wang, Yong, Huang, Yuqian, Cui, Yaping, Xia, Lin, Chen, Yi, Zhuang, Wen, Zhou, Yong, Wu, Xiaoting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715066/
https://www.ncbi.nlm.nih.gov/pubmed/29203825
http://dx.doi.org/10.1038/s41598-017-17266-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715066/
https://www.ncbi.nlm.nih.gov/pubmed/29203825
http://dx.doi.org/10.1038/s41598-017-17266-5

Ejemplares similares